CombinatoRx (CRXX) Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009
More News related to CRXX
- CombinatoRx, Inc. (CRXX) and Neruomed Pharma Receive U.S. FDA Letter Regarding NDA for Exalgo
- FDA Extends NDA Review for Exalgo(TM) Extended-Release Tablets
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Morning Movers 11/16: SPEX, NLST, XJT, NABI, KHD, IBKC, SPA Higher; PARD, CRXX, CAEI Lower
- Biotech Movers: SPEX, NABI, ALKS Up; PARD, CRXX Down
CombinatoRx, Incorporated (NASDAQ: CRXX) announced the presentation of full data on Synavive (CRx-102) Phase 2 knee osteoarthritis (OA) trial (COMET-1) at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009. The presentation, "CRx-102, a dissociated glucocorticoid (GC), and prednisolone provide safe and effective pain relief in knee osteoarthritis (OA) in a placebo-controlled Phase 2 trial (COMET-1)", Huttner et.al., describes the full, modified intent-to-treat, safety and efficacy results of Synavive in this clinical trial:
-- Knee OA efficacy was observed early in treatment and sustained throughout the study in all WOMAC measurement subscales including pain, physical function and stiffness
-- Combination effects of Synavive were observed in comparison to prednisolone alone, especially in those subjects with greater disease burden
-- In comparison to prednisolone alone, reduction in hand OA pain was observed early with Synavive and sustained throughout the study.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.19Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
